Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-06-29

Clinical Trial Update: Study of ASN51 in Adults With Early Alzheimer's Disease [Phase 2]

View source ↗

Summary

A Phase 2 study of ASN51 for adults with early Alzheimer's disease was terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ASN51 (ASN-51)

Snippet

Sponsor: Asceneuron S.A. | Conditions: Alzheimer Disease | Phase 2 | Status: TERMINATED | Results posted: 2025-06-29